Mineralys Therapeutics, Inc.

150 N. Radnor Chester Road, Suite F200

Radnor, PA 19087

February 7, 2023

VIA EDGAR

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

Re:			Mineralys Therapeutics, Inc.
			Registration Statement on Form S-1, as amended
			File No. 333-269282

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on February 9, 2023, or as soon as practicable thereafter.

Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.

Very truly yours,
MINERALYS THERAPEUTICS, INC.
By:			/s/ Jon Congleton
			Jon Congleton
			Chief Executive Officer

cc:			Adam Levy, Mineralys Therapeutics, Inc.
			Cheston J. Larson, Latham & Watkins LLP
			Matthew T. Bush, Latham & Watkins LLP
			Ilir Mujalovic, Shearman & Sterling LLP